Esperion Long Term Data On Cholesterol Medication’s Ability To Cut Cardiovascular Risk Fails To Impress Investors
Esperion Therapeutics Inc (NASDAQ:ESPR) announced the full results from the CLEAR Outcomes trial, a global study of nearly 14,000 patients with…